US 12,472,246 B2
Coronavirus vaccine formulations
Gale Smith, Germantown, MD (US); Michael J. Massare, Mt. Airy, MD (US); and Jing-Hui Tian, Germantown, MD (US)
Filed by Novavax, Inc., Gaithersburg, MD (US)
Filed on Dec. 5, 2022, as Appl. No. 18/061,831.
Application 18/061,831 is a continuation of application No. 17/170,367, filed on Feb. 8, 2021, granted, now 11,541,112.
Application 17/170,367 is a continuation of application No. 16/997,001, filed on Aug. 19, 2020, granted, now 10,953,089, issued on Mar. 23, 2021.
Claims priority of provisional application 63/054,182, filed on Jul. 20, 2020.
Claims priority of provisional application 63/051,706, filed on Jul. 14, 2020.
Claims priority of provisional application 63/048,945, filed on Jul. 7, 2020.
Claims priority of provisional application 62/983,180, filed on Feb. 28, 2020.
Claims priority of provisional application 62/976,858, filed on Feb. 14, 2020.
Claims priority of provisional application 62/966,271, filed on Jan. 27, 2020.
Prior Publication US 2023/0330216 A1, Oct. 19, 2023
This patent is subject to a terminal disclaimer.
Int. Cl. A61K 39/215 (2006.01); A61P 31/14 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61P 31/14 (2018.01); A61K 2039/545 (2013.01); A61K 2039/55577 (2013.01); C12N 2770/20034 (2013.01)] 12 Claims
OG exemplary drawing
 
1. A method of stimulating an immune response against SARS-CoV-2 in a human comprising administering an immunogenic composition to the human, wherein the immunogenic composition compromises:
(i) a nanoparticle comprising coronavirus S (CoV S) glycoprotein trimers and a non-ionic detergent core,
wherein individual CoV S glycoproteins of the glycoprotein trimers comprise a sequence that is at least 95% identical to SEQ ID NO: 2;
wherein amino acids 669-672 of the CoV S individual glycoproteins are QQAQ (SEQ ID NO: 7) and amino acids 973 and 974 are proline,
wherein said amino acids are numbered with respect to SEQ ID NO: 2; and
(ii) a saponin adjuvant;
wherein the immunogenic composition comprises from about 3 μg to about 25 μg of the CoV S glycoprotein, and
wherein the immunogenic composition comprises from about 1 μg to about 100 μg of adjuvant.